drugset / Trial / NCT04865419

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

NCT04865419

Phase 1 Terminated 46 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.

Timeline

Start
2021-06-11
Primary completion
2023-08-08
Completion
2023-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD0466 Unknown Intravenous
Subject Voriconazole Small molecule Oral